X0306 4 2018-11-02 0 0001603756 Axonics Modulation Technologies, Inc. AXNX 0001757283 Andera Partners 374 RUE SAINT ST HONORE ST. 75001 PARIS 0 0 1 0 0001756321 BioDiscovery 4 FCPR 374 RUE SAINT ST HONORE ST. 75001 PARIS 0 0 1 0 Common Stock 2018-11-02 4 C 0 799228 A 799228 I See footnote Common Stock 2018-11-02 4 C 0 806080 A 1605308 I See footnote Common Stock 2018-11-02 4 C 0 431250 A 2036558 I See footnote Common Stock 2018-11-02 4 C 0 654237 A 2690795 I See footnote Common Stock 2018-11-02 4 P 0 866666 15.00 A 3557461 I See footnote Series A Preferred Stock 2018-11-02 4 C 0 345000 0.00 D Common Stock 799228 0 I See footnote Series B-1 Preferred Stock 2018-11-02 4 C 0 671733 0.00 D Common Stock 806080 0 I See footnote Series B-2 Preferred Stock 2018-11-02 4 C 0 359375 0.00 D Common Stock 431250 0 I See footnote Series C Preferred Stock 2018-11-02 4 C 0 545197 0.00 D Common Stock 654237 0 I See footnote Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018. Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series A preferred stock automatically converted into 2.31660 shares of the Issuer's common stock. The A preferred stock had no expiration date. This report is filed jointly by Andera Partners ("Andera") and BioDiscovery 4 FCPR ("BioDiscovery"). 2,824,128 shares are held of record by BioDiscovery and 733,333 shares are held of record by BioDiscovery 5 ("BioDiscovery 5"). Andera is the manager of BioDiscovery and BioDiscovery 5 and may be deemed to have sole voting and dispositive power over the shares held by BioDiscovery and BioDiscovery 5. Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series B-1 preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The B-1 preferred stock had no expiration date. Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series B-2 preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The B-2 preferred stock had no expiration date. Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The C preferred stock had no expiration date. /s/ Aichatou DIOP for Andera Partners 2018-11-02 /s/ Aichatou DIOP for BioDiscovery 4 FCPR 2018-11-02